Abstract
FOXP3+ regulatory T cells (Tregs) represent a promising platform for effective adoptive immunotherapy of chronic inflammatory disease, including autoimmune diseases such as multiple sclerosis. Successful Treg immunotherapy however requires new technologies to enable long-term expansion of stable, antigen-specific FOXP3+ Tregs in cell culture. Antigen-specific activation of naïve T cells in the presence of TGF-β elicits the initial differentiation of the FOXP3+ lineage, but these Treg lines lack phenotypic stability and rapidly transition to a conventional T cell (Tcon) phenotype during in vitro propagation. Because Tregs and Tcons differentially express CD25, we hypothesized that anti-CD25 monoclonal antibodies (mAbs) would only partially block IL-2 signaling in CD25high FOXP3+ Tregs while completely blocking IL-2 responses of CD25low-intermediate Tcons to enable preferential outgrowth of Tregs during in vitro propagation. Indeed, murine TGF-β-induced MOG-specific Treg lines from 2D2 transgenic mice that were maintained in IL-2 with the anti-CD25 PC61 mAb rapidly acquired and indefinitely maintained a FOXP3high phenotype during long-term in vitro propagation (>90% FOXP3+ Tregs), whereas parallel cultures lacking PC61 rapidly lost FOXP3. These results pertained to TGF-β-inducible “iTregs” because Tregs from 2D2-FIG Rag1−/− mice, which lack thymic or natural Tregs, were stabilized by continuous culture in IL-2 and PC61. MOG-specific and polyclonal Tregs upregulated the Treg-associated markers Neuropilin-1 (NRP1) and Helios (IKZF2). Just as PC61 stabilized FOXP3+ Tregs during expansion in IL-2, TGF-β fully stabilized FOXP3+ Tregs during cellular activation in the presence of dendritic cells and antigen/mitogen. Adoptive transfer of blastogenic CD25high FOXP3+ Tregs from MOG35-55-specific 2D2 TCR transgenic mice suppressed experimental autoimmune encephalomyelitis in pretreatment and therapeutic protocols. In conclusion, low IL-2 concentrations coupled with high PC61 concentrations constrained IL-2 signaling to a low-intensity range that enabled dominant stable outgrowth of suppressive CD25high FOXP3+ Tregs. The ability to indefinitely expand stable Treg lines will provide insight into FOXP3+ Treg physiology and will be foundational for Treg-based immunotherapy.
Highlights
CD4+ CD25+ FOXP3+ regulatory T cells (Tregs) mediate an integral role in controlling autoimmunity and chronic inflammatory disorders [1, 2]
To optimize antigen-dependent induction of Tregs, designated concentrations of MOG35-55 were used to activate 2D2-Foxp3-IRES-gating on Vβ11 and FOXP3 (GFP) knock-in (FIG) SPL in the presence of 10 nM TGF-β (Figure 1). 2D2-FIG T cells are specific for MOG35-55 and have an IRES-GFP reporter knock-in immediately downstream of the FOXP3 gene
After 3 days, 320 nM or 1 μM MOG35-55 elicited percentages of FOXP3+ Tregs (54 and 60%, respectively) that were significantly higher than the 40% Tregs induced by the higher concentrations of 3.2 and 10 μM MOG35-55 (Figures 1A,C)
Summary
CD4+ CD25+ FOXP3+ regulatory T cells (Tregs) mediate an integral role in controlling autoimmunity and chronic inflammatory disorders [1, 2]. Dysfunctional Treg responses have been implicated in susceptibility to several autoimmune diseases including multiple sclerosis and type 1 diabetes [4]. Treg-mediated suppressive activity has promise for translation as an immunotherapy for autoimmune disease and other chronic inflammatory disorders. Treg adoptive immunotherapy is based on the concept that Tregs can be isolated or induced ex vivo, expanded as a stable subset in vitro, and infused into a syngeneic recipient to inhibit autoimmune inflammation. In early phase clinical trials, Treg-based immunotherapies for transplantation and type 1 diabetes have had favorable outcomes [8, 9]. Adoptive Treg immunotherapy has yet to be approved as a treatment option due to technical limitations associated with Treg instability during in vitro expansion
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.